TNGX

Tango Therapeutics Stock Jumps 21% Premarket After 82% Pancreatic Cancer Response Data — Phase 3 Is Next

2026-10-23

Tango Therapeutics (NASDAQ: TNGX) jumped about 21% in premarket trading on Friday, October 23, 2026, after the company reported an 82% objective response rate for its vopimetostat plus daraxonrasib...